손해배상(기)
1. The judgment of the court of first instance is modified as follows.
The Defendants jointly do so to the Plaintiff and jointly do so. 205,240,000 won.
1. Basic facts
A. The Plaintiff is a company whose main business is the research, development, and manufacture of bio-pharmaceutical drugs, such as the one-sharing dysium using the one-sharing dysium type (hereinafter “instant products”). Defendant B Co., Ltd. (hereinafter “Defendant Company”) is a company that provides articles related to medical services to the website (hereinafter “instant website”) while engaging in the Internet medical information providing business, etc., and Defendant C is a reporter of the Defendant Company.
B. On April 13, 2017, the Defendant joining the Defendant posted the following articles on the H website (I) around 11:53 on April 13, 2017.
[단독] J 미간주름 개선 등 주로 미용성형에 쓰이는 국내 보툴리눔톡신 제제에서 중대한 약물 이상반응 사례가 나타난 것으로 확인됐다.
The Botul Sharing Center is a drug that requires attention to life by causing conflicts of interest, such as hurficism and hurficism, which has spread from the part of the hurf to another part of the body of the hurf.
In fact, many cases of death have been reported as Germany spread.
After the Ministry of Food and Drug Safety conducted a survey on the "F" for the six years after the market, the Ministry of Food and Drug Safety stated that the 13th day of the 10 patient suffering from the 10th stalm of the 10 patient suffering from the 10th stalm of the 13th stalm of the 10 patient suffering from
F has four types of adaptation, such as training of adults aged between 18 and 65, temporary improvement of liverer care for adults aged between 18 and 65, temporary improvement of liverer care for adults aged between 18 and 65, strokeer care related to strokeer care for adults aged 20 or older, strokeer care related to strokeer care for adults aged 20 or older, and strokeer care for strokeer care for patients aged 2 or older.
First of all, the 695 patients with the main visual gymosis showed abnormal reactions to 147 persons as a result of the results of the use of the market after the market.
among them.